Cargando…

Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study

BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Nicole, Mitterbauer, Margit, Tobudic, Selma, Kalhs, Peter, Rabitsch, Werner, Greinix, Hildegard, Burgmann, Heinz, Willinger, Birgit, Presterl, Elisabeth, Forstner, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696168/
https://www.ncbi.nlm.nih.gov/pubmed/26715563
http://dx.doi.org/10.1186/s12879-015-1329-6
_version_ 1782407741413785600
author Harrison, Nicole
Mitterbauer, Margit
Tobudic, Selma
Kalhs, Peter
Rabitsch, Werner
Greinix, Hildegard
Burgmann, Heinz
Willinger, Birgit
Presterl, Elisabeth
Forstner, Christina
author_facet Harrison, Nicole
Mitterbauer, Margit
Tobudic, Selma
Kalhs, Peter
Rabitsch, Werner
Greinix, Hildegard
Burgmann, Heinz
Willinger, Birgit
Presterl, Elisabeth
Forstner, Christina
author_sort Harrison, Nicole
collection PubMed
description BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group. All adult patients (n = 242) receiving an allogeneic HSCT at the University Hospital of Vienna from January 2009 to December 2013 were enrolled. RESULTS: The primary outcome of this study was the one-year incidence for IFDs after HSCT, which was 10.3 % (25/242). Overall 28 patients experienced an IFD – 20 probable and 8 proven – with invasive aspergillosis being the predominant IFD (n = 18), followed by invasive candidiasis (n = 7) and pneumocystis pneumonia (n = 3). Patients with an IFD were more likely to be admitted to an intensive care unit (64 % versus 12 %, p < 0.0001) and had a significantly higher mortality in the first year after HSCT (48 % versus 25 %, p = 0.02). Multivariate regression analysis revealed that intensified immunosuppressive therapy (high-dose cortisone and basiliximab or etanercept) because of severe graft-versus-host disease (adjusted odds ratio (AOR) 3.6, p = 0.01) and transplant-associated microangiopathy (AOR 3.7, p = 0.04) were associated with an increased risk for IFD, while antifungal prophylaxis given during aplasia and post-engraftment was associated with a decreased risk (AOR 0.3, p = 0.02). CONCLUSIONS: We documented a one-year incidence for IFDs of 10.3 % and no selection of rare pathogens at a centre with moderate use of antifungal prophylaxis. Intensified immunosuppressive therapy and transplant-associated microangiopathy were significant risk factors for IFDs.
format Online
Article
Text
id pubmed-4696168
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46961682015-12-31 Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study Harrison, Nicole Mitterbauer, Margit Tobudic, Selma Kalhs, Peter Rabitsch, Werner Greinix, Hildegard Burgmann, Heinz Willinger, Birgit Presterl, Elisabeth Forstner, Christina BMC Infect Dis Research Article BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group. All adult patients (n = 242) receiving an allogeneic HSCT at the University Hospital of Vienna from January 2009 to December 2013 were enrolled. RESULTS: The primary outcome of this study was the one-year incidence for IFDs after HSCT, which was 10.3 % (25/242). Overall 28 patients experienced an IFD – 20 probable and 8 proven – with invasive aspergillosis being the predominant IFD (n = 18), followed by invasive candidiasis (n = 7) and pneumocystis pneumonia (n = 3). Patients with an IFD were more likely to be admitted to an intensive care unit (64 % versus 12 %, p < 0.0001) and had a significantly higher mortality in the first year after HSCT (48 % versus 25 %, p = 0.02). Multivariate regression analysis revealed that intensified immunosuppressive therapy (high-dose cortisone and basiliximab or etanercept) because of severe graft-versus-host disease (adjusted odds ratio (AOR) 3.6, p = 0.01) and transplant-associated microangiopathy (AOR 3.7, p = 0.04) were associated with an increased risk for IFD, while antifungal prophylaxis given during aplasia and post-engraftment was associated with a decreased risk (AOR 0.3, p = 0.02). CONCLUSIONS: We documented a one-year incidence for IFDs of 10.3 % and no selection of rare pathogens at a centre with moderate use of antifungal prophylaxis. Intensified immunosuppressive therapy and transplant-associated microangiopathy were significant risk factors for IFDs. BioMed Central 2015-12-29 /pmc/articles/PMC4696168/ /pubmed/26715563 http://dx.doi.org/10.1186/s12879-015-1329-6 Text en © Harrison et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Harrison, Nicole
Mitterbauer, Margit
Tobudic, Selma
Kalhs, Peter
Rabitsch, Werner
Greinix, Hildegard
Burgmann, Heinz
Willinger, Birgit
Presterl, Elisabeth
Forstner, Christina
Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title_full Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title_fullStr Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title_full_unstemmed Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title_short Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
title_sort incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696168/
https://www.ncbi.nlm.nih.gov/pubmed/26715563
http://dx.doi.org/10.1186/s12879-015-1329-6
work_keys_str_mv AT harrisonnicole incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT mitterbauermargit incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT tobudicselma incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT kalhspeter incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT rabitschwerner incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT greinixhildegard incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT burgmannheinz incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT willingerbirgit incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT presterlelisabeth incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy
AT forstnerchristina incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy